Tyra Biosciences (TYRA)
(Delayed Data from NSDQ)
$18.44 USD
-0.14 (-0.75%)
Updated May 15, 2024 04:00 PM ET
After-Market: $18.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Tyra Biosciences, Inc. [TYRA]
Reports for Purchase
Showing records 21 - 33 ( 33 total )
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Orphan Drug Designation Granted in Achondroplasia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $27 PT; Surfing the Next Wave of FGFRi
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Initiating at OUTPERFORM and $27 PT; Surfing the Next Wave Of FGFRi
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Two Clinical-Stage Programs by YE23; 1Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Timelines on Track; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Achondroplasia Data Mitigates TYRA-300 Risk; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Being Developed in Achondroplasia; Raising PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Patient Dosing Initiation Marks Move Into Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Phase 1/2 Trial Starting Soon; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Data at ESMO Validates Selective FGFR2 Approach; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
TYRA-300 Clinical Study Initiation Imminent; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Tyra Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Purpose-Built Targeted Therapy for Cancer; Initiating at Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M